[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hanson Medical, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100647058","scar-gel-product-family-clinical-investigation-100647058",false,"NCT07684573","Scar Gel Product Family Clinical Investigation","PMCF Investigation to Compare the Clinical Performance\u002FBenefit of Dermatix With Dermatix Ultra","Inclusion Criteria:\n\n* Patients aged \\>3 years.\n* Patients with keloids and hypertrophic scars (such as those resulting from general surgical procedures, trauma wounds, and burns), i.e., older scars.\n* Patients at risk of developing keloids and hypertrophic scars, i.e., recent scars.\n\nExclusion Criteria:\n\n* Patients with unhealed and\u002For open wounds.\n* Patients with allergies to any of the ingredients.\n* Pregnant or breastfeeding women.\n* Patients using other topical skin treatments on\u002Faround the scar area.","ALL","3 Years",{"count":19,"type":20},150,"ESTIMATED","OBSERVATIONAL","The purpose of this PMCF investigation is to determine whether there are differences between the two formulations (Dermatix and Dermatix Ultra) in improving keloid and hypertrophic scars clinical symptoms and in the overall scar perception (including scar appearance and treatment perception).\n\nThis PMCF investigation has been designed to address the conclusions of the latest CER \\[PDPROJ-4-CE-R\\] and the objectives. It has been chosen as an appropriate activity as it enables the collection of device-specific data on both device formulations and on the entire intended population. Moreover, the design of the PMCF investigation (single-center, parallel, open-label, two-arm, randomized controlled study) enables the direct comparison of the clinical performance\u002Fbenefit between the two formulations.",[24,25],"Hypertrophic Scars","Keloids","NOT_YET_RECRUITING","2026-06-29",{"date":29,"type":30},"2026-07-06","ACTUAL",{"date":32,"type":20},"2026-07",{"date":34,"type":20},"2026-12",{"name":36,"class":37},"Hanson Medical, Inc.","INDUSTRY",""]